Author

Ji Hwa Ryu

Institution: SK bioscience Co., Ltd. (South Korea)

Observed institutions: SK bioscience Co., Ltd. (South Korea), Sungkyunkwan University

ORCID: 0000-0001-5934-0905

Observed ORCID: 0000-0001-5934-0905

OpenAlex ID: A5001472174

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial

2022 · Joon Young Song, Won Suk Choi, et al. · EClinicalMedicine · 96

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial

2023 · Joon Young Song, Won Suk Choi, et al. · EClinicalMedicine · 54

Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6–35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial

2026 · Yoonsun Yoon, Hye-Kyung Cho, et al. · Vaccines · 1

Cardiovascular Safety of COVID-19 Vaccination in Patients With Cancer: A Self-Controlled Case Series Study in Korea

2024 · Ji Hwa Ryu, Ahhyung Choi, et al. · Journal of Korean Medical Science · 1

Works count: 4

Citation count: 152

H-index: 2

I10-index: 2